On-Demand: Public Markets’ Impact on Manufacturing Advanced Therapies
Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.
Publication: Value of a Cure for Sickle Cell Disease in Reducing Economic Disparities
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
Click here to learn more about the model and the team’s findings.
White Paper: What’s Next for Advanced Therapies?
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.
This white paper is based on a panel discussion sponsored by Precision ADVANCE at the 2021 Meeting on the Mesa conference and features insights from C-suite leaders on the current CGTx investment landscape, technology innovations, talent shortage and the evolution of reimbursement payment models.
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- R.A. Session II: President, Founder and CEO (Taysha Gene Therapies)
- Palani Palaniappan: EVP and CTO (Aruvant Sciences)
- Derrell Porter: Founder and CEO (Cellevolve Bio)
- Claudia Zylberberg: Founder and Executive Chair (Akron Bio)
- Phil Cyr: SVP (Precision Value & Health)
Conference: ASGCT Annual Meeting, 2022
Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.
Article: A Shared Opportunity – The Future of Cell and Gene Therapy
The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.